The OPTIMA Verdict: Two-Thirds of High-Risk Breast Cancer Patients Can Safely Skip Chemotherapy

A 50-gene tumor test has proven that most women and men steered toward chemotherapy for breast cancer based on clinical features alone do not actually need it.

Presented By Our Partners

For decades, one of the most difficult conversations in oncology has unfolded in exam rooms around the world. A woman is diagnosed with early-stage breast cancer. Her tumor is estrogen receptor (ER)-positive, HER2-negative. The nodes are involved. By every clinical measure, she qualifies for adjuvant chemotherapy. The oncologist recommends it. And so she endures months of nausea, fatigue, infection risk, and the long shadow of cognitive side effects, all for a treatment that may deliver little benefit for her specific tumor biology.

That scenario just became dramatically less likely.

Results from the OPTIMA trial, a phase 3 randomized controlled study of 4,429 patients across six countries, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 30. The findings, led by Professor Robert C. Stein of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, showed that a 50-gene genomic test called Prosigna can safely identify which high-risk breast cancer patients actually need chemotherapy and which ones do not. The answer: approximately 68 percent of patients with clinical risk features qualifying them for chemotherapy turned out to have low-risk tumors at the genomic level, and those patients did just as well with hormone therapy alone.

The Clinical Problem OPTIMA Was Built to Solve

Breast cancer treatment has always operated under a fundamental tension. Clinical staging, which includes tumor size, lymph node involvement, and grade, does an excellent job of identifying patients at elevated risk of recurrence. But clinical risk and biological risk are not the same thing. A tumor that looks aggressive under the microscope may carry a genomic fingerprint that reads: this cancer will not respond meaningfully to chemotherapy, and hormone therapy alone will do the job.

This gap between clinical appearance and tumor biology has led to what researchers have long believed is widespread overtreatment. Patients with node-positive disease especially have been systematically steered toward chemotherapy because, historically, the presence of cancer in lymph nodes was treated as a near-automatic trigger. The tools to interrogate tumor biology more precisely existed in theory, but the randomized trial data to support using them in high-risk, node-positive patients was largely absent.

That is precisely what OPTIMA set out to generate.

The trial enrolled 4,429 women and men aged 40 or older who were clinically recommended to receive adjuvant chemotherapy for ER-positive, HER2-negative early breast cancer. Patients had between zero and nine involved axillary lymph nodes. Crucially, many had significant nodal burden: 73 percent had pN1 or pN1sn tumors, and 19 percent had pN2 disease, meaning cancer had spread to four or more regional lymph nodes. This was not a low-risk population. These were patients oncologists would, under standard guidelines, almost certainly send to chemotherapy.

The trial was conducted across the United Kingdom, Norway, Sweden, Australia, New Zealand, and Thailand, with co-chief investigation led by Professor Iain MacPherson of the University of Glasgow.

How the Prosigna Test Works

Prosigna, developed by Veracyte and based on the PAM50 gene expression assay, analyzes the activity of 50 genes within a tumor biopsy sample. The test generates a Risk of Recurrence (ROR) score that estimates the likelihood the cancer will spread to distant organs within ten years. The score also places tumors into intrinsic biological subtypes: Luminal A, Luminal B, HER2-enriched, and Basal-like.

In the OPTIMA trial protocol, patients who received the Prosigna test were assigned to two pathways based on their ROR score. Those with a score above 60 proceeded to standard chemotherapy followed by endocrine therapy. Those with a score of 60 or below received endocrine therapy alone. For premenopausal women in the hormone-therapy arm, endocrine therapy included ovarian function suppression, an important intensification that ensures adequate estrogen suppression without cytotoxic treatment.

The test-directed arm was then compared for noninferiority against the control group, which received standard chemotherapy followed by endocrine therapy regardless of genomic results.

The Numbers That Change Practice

The primary endpoint was 5-year invasive breast cancer-free survival (IBCFS). In the per-protocol population, the test-directed arm achieved a 5-year IBCFS rate of 90.3 percent, compared with 91.8 percent in the control arm. The adjusted hazard ratio was 1.03 with a 90 percent confidence interval of 0.85 to 1.25, meeting the trial’s predefined noninferiority margin.

In other words, directing treatment based on the genomic test rather than clinical features alone produced survival outcomes that were effectively equivalent to giving everyone chemotherapy.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The picture sharpens when you look specifically at the patients who most stood to benefit from the de-escalation strategy. Among patients with low ROR scores who received endocrine therapy alone in the test-directed arm, the 5-year IBCFS was 93.6 percent. The comparable figure for patients in the same clinical-risk tier who received standard chemotherapy in the control arm was 94.8 percent. The adjusted hazard ratio for this subgroup was 1.06, with a 90 percent confidence interval of 0.80 to 1.40. Again, noninferior. For these patients, the survival curves were essentially on top of each other, and chemotherapy added no meaningful protection.

The trial also examined the distant recurrence-free interval, the metric that most directly captures the fear underlying chemotherapy decisions, namely whether cancer spreads to bones, lungs, liver, or brain. That outcome, too, was similar between the arms.

Who This Affects and Why the Scale Matters

The clinical significance of the OPTIMA result scales with how many patients fall into the newly redefined low-risk genomic category. The answer, in OPTIMA, was 68 percent. More than two in three patients who qualified for chemotherapy based on standard clinical criteria turned out to have tumors the Prosigna test classified as low-risk at the genomic level.

That figure has real-world implications that are difficult to overstate. In the United States alone, roughly 300,000 women are diagnosed with invasive breast cancer each year. The majority are ER-positive, HER2-negative, the specific subtype OPTIMA studied. A meaningful proportion of those have node-positive disease that would historically trigger chemotherapy discussions. If the OPTIMA findings hold across broader populations, the number of patients who can avoid chemotherapy and its attendant toxicities could be in the tens of thousands annually in the United States alone, with proportional impact across Europe, Australia, and the rest of the developed world.

“We have shown that patients with low ROR score tumors gain minimum, if any, chemotherapy benefit,” said Dr. Stein at the ASCO podium. “Whilst our result applies to our entire population, we have shown that Prosigna can safely assist adjuvant chemotherapy decisions in premenopausal women aged at least 40 years treated with ovarian function suppression and patients with four to nine involved lymph nodes or stage IIIA tumors.”

That last point is noteworthy. The node-positive patients in OPTIMA represent a group that oncologists have historically been most reluctant to spare from chemotherapy. The four-to-nine-node tier in particular has been treated as near-automatic indication for cytotoxic therapy. OPTIMA’s genomic-guided approach now challenges that instinct with randomized evidence.

The Discussant’s Verdict and What It Signals

At major oncology trials, the discussion of results by a senior expert is often as important as the data itself. At ASCO 2026, that role fell to Professor Martine J. Piccart-Gebhart of the Jules Bordet Institute at the Université Libre de Bruxelles in Belgium, one of the leading breast oncology researchers in the world.

Her response was significant. Piccart-Gebhart announced she will now recommend a genomic assay for all post- and premenopausal women older than 40 with any number of positive nodes. “A ‘low-risk’ genomic test result will trigger shared decision-making based on trade-off regarding chemotherapy yes or no in the presence of optimal endocrine therapy,” she said.

This is not a throwaway comment from a discussant looking to be diplomatic. Piccart-Gebhart is pointing to a shift in the default: from assuming chemotherapy is needed unless proven otherwise, to using genomic evidence as the primary guide, with the decision carried out collaboratively between the oncologist and the patient. That is a meaningful evolution in how the field approaches a conversation that has, for many patients, felt terrifying and predetermined.

She did add appropriate caution: “Some uncertainty remains in view of the relatively small key subgroup populations and short follow-up in the OPTIMA trial.” That caveat matters and deserves serious attention.

The Honest Limitations

Dr. Stein was transparent about OPTIMA’s constraints, and they deserve careful examination rather than dismissal.

The most significant limitation is follow-up time. Fewer than 40 percent of patients had reached the 5-year mark at the time of analysis, which is why the confidence intervals remain relatively wide. Breast cancer recurrence in ER-positive disease can occur late, sometimes ten to fifteen years after initial diagnosis. Five-year data, while reassuring, may not fully capture the tail-end risk that distinguishes node-positive from node-negative disease.

There is also the question of generalizability. Approximately 90 percent of OPTIMA participants self-described as white, a demographic skew that limits how confidently the findings can be applied to Black, Hispanic, Asian, and other non-white patients. Breast cancer biology can differ across racial and ethnic groups, and the performance of genomic tests across those groups remains an area requiring additional dedicated research.

The confidence intervals in several key subgroups are wide enough that uncertainty persists. OPTIMA is designed as a noninferiority trial, meaning it is powered to show that the genomic approach is not substantially worse than chemotherapy, not that it is equivalent or superior. That is the appropriate statistical question, but it means the data are not designed to detect small differences in favor of chemotherapy that might still matter to some individual patients.

What Comes Next

Two large prospective trials are actively working to extend and confirm the OPTIMA findings. OFSET, enrolling patients in the United States (NCT05879926), and OPTIMA-YOUNG, running across Europe with a focus on younger premenopausal patients (NCT07106632), will generate additional randomized evidence. The results from both will take years to mature, but they represent the natural scientific extension of OPTIMA’s core question.

There is a complication on the horizon that Piccart-Gebhart flagged: CDK 4/6 inhibitors, a class of targeted therapies that have transformed ER-positive breast cancer treatment in the metastatic setting, are now being incorporated into adjuvant protocols and are allowed in both OFSET and OPTIMA-YOUNG. Because CDK 4/6 inhibitors appear to add benefit independent of chemotherapy in certain patient groups, their inclusion could make it harder to isolate the specific chemotherapy contribution in future trials. The oncology field will need to continue evolving its analytical frameworks as the treatment landscape grows more complex.

The existing landscape of genomic testing in breast cancer also provides useful context. The Oncotype DX Recurrence Score, which preceded Prosigna as a commercial genomic assay, was validated in the TAILORx and RxPONDER trials and is now embedded in guidelines from ASCO and the National Comprehensive Cancer Network (NCCN). Prosigna and Oncotype DX analyze different gene sets and generate different scores, but both aim to resolve the same fundamental clinical question: given this patient’s tumor biology, does chemotherapy add survival benefit beyond endocrine therapy? OPTIMA now adds phase 3 randomized evidence to support Prosigna’s role in that framework, particularly for node-positive patients where evidence has historically been thinner.

Genomics as the Standard, Not the Exception

OPTIMA reflects a broader shift in oncology that has been building for more than a decade: the move from population-level treatment protocols toward biology-first, patient-specific decision-making. The same principle that drives targeted immunotherapies, bispecific antibodies, and AI-driven diagnostics applies here, though more quietly. The insight is simple: the same disease looks different at the molecular level from one patient to the next, and treatments designed around population averages will inevitably overtreat some patients and undertreat others.

What OPTIMA proves, with randomized controlled trial rigor across more than four thousand patients in six countries, is that a commercially available, clinically practical genomic test can reliably identify the overtreated group in ER-positive, HER2-negative breast cancer. Roughly two-thirds of those patients qualify. Sparing them from chemotherapy does not compromise their survival. And the harm avoided, the nausea, fatigue, immunosuppression, peripheral neuropathy, and long-term cognitive effects that accompany cytotoxic therapy, is real and significant.

This is precision medicine not as a theoretical aspiration but as a delivered, measurable clinical reality: enrolled in real hospitals, tested against the standard of care, and published in the Journal of Clinical Oncology.

What This Means for You

If you or someone you care about has been diagnosed with ER-positive, HER2-negative early breast cancer, the OPTIMA results create a direct and concrete question worth raising with your oncologist: has a genomic risk assessment been ordered, and which test was used?

The Prosigna test (based on the PAM50 assay) is commercially available in the United States, United Kingdom, and several other countries. The ROR score it generates now has phase 3 randomized evidence supporting its use as a decision-making tool in patients with clinically high-risk features, including those with four or more positive lymph nodes, a group historically assumed to need chemotherapy.

A low ROR score of 60 or below does not automatically eliminate chemotherapy from the picture. It creates the basis for a shared decision-making conversation: given that the genomic evidence suggests minimal chemotherapy benefit, are the toxicities and quality-of-life costs of treatment worth pursuing? For most patients in the low-risk tier, OPTIMA’s data suggests the answer is no.

That conversation, grounded in real genomic evidence from your specific tumor, is now both possible and supported by the strongest level of clinical evidence available. The tool exists. The trial exists. The question is whether every eligible patient gets the chance to ask it.

If you are newly diagnosed and facing a chemotherapy recommendation, ask your care team whether a genomic tumor test has been performed, and specifically whether your tumor biology justifies cytotoxic treatment in light of the OPTIMA findings. You may be among the two-thirds.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.